15.04.2013 - French green plastics company Carbios has secured exclusive patent rights from a collaboration with the National Institute for Agricultural Research.
The five-year collaboration of Carbios (Clermon-Ferrant) and INRA (Paris) at the Toulouse White Biotechnology (TWB) research centre is part of the €22m THANAPLAST™ private-public consortium on plastics, comprising the CNRS, INRA, the Université de Poitiers, Deinove, the Barbier Group, and the Limagrain Group.
The Carbios-INRA project will focus on the development of bioprocesses for recovering plastic waste and producing economically competitive bio-based polymers. The interdisciplinary collaboration will include R&D staff from TWB, the 3BCar Carnot Institute and two INRA groups. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.
Carbios is developing solutions for transforming the global supply of over 100 million tons of plastic waste into a novel, high-quality, renewable raw material for the plastics industry. The company offers a viable economic alternative to the depletion of agricultural resources and the rarefaction of fossil fuels.
Carbios CEO Jean-Claude Lumaret commented that "although Europe generates almost 25 million metric tons of plastic waste each year, only 20% of that is recycled. The recovery of such an important renewable resource is a key business issue. We are delighted to have signed this partnership agreement with LISBP and Micalis - two INRA R&D groups that are internationally renowned for their know-how and expertise in enzymatic bioprocesses. By combining our skills and resources, the resulting synergy will be an impressive driver for innovation and the development of breakthrough industrial bioprocesses".
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.